Key result
Inotropes linked to ~56% lower NT-proBNP and improved GFR in acute decompensated heart failure.
Why the study?
Little is known regarding the effect of inotropic therapy on the interplay of hemodynamics, biomarkers, and end-organ function across different HF etiologies and rhythms.
Does dobutamine or levosimendan improve hemodynamics, biomarkers, and renal function in patients with acute decompensated heart failure?
Cohort (n=50)
No
Does dobutamine or levosimendan improve hemodynamics, biomarkers, and renal function in patients with acute decompensated heart failure?
Answers are grounded in this paper and cite their sources.
Inotropic therapy with dobutamine or levosimendan in acute decompensated heart failure improves biomarkers and renal function, with hemodynamic benefits primarily seen in patients with dilated cardiomyopathy, sinus rhythm, or those receiving levosimendan.
BACKGROUND: Little is known about the impact of treatment with inotropic drugs on the interaction of hemodynamics, biomarkers, and end-organ function in patients with acute decompensated heart failure (HF) of different origins and heart rhythms. METHODS: Fifty patients with different causes of acute decompensated HF (dilated cardiomyopathy DCM, ischemic cardiomyopathy ICM, atrial fibrillation AF, sinus rhythm/pacemaker lead rhythm SR/PM) were treated with dobutamine or levosimendan. Non-invasive hemodynamics, biomarkers, and parameters of renal organ function were evaluated at hospital admission and after myocardial recompensation (day 5 to 7). RESULTS: Twenty-seven patients with ICM and twenty-three patients with DCM were included. Thirty-nine patients were treated with dobutamine and eleven with levosimendan. Sixteen were accompanied by persistent AF and thirty-four presented either with SR or PM. In the overall cohort, body weight and biomarkers (NT-proBNP/ST2) significantly decreased. GFR significantly increased during therapy with either dobutamine or levosimendan. However, hemodynamic parameters seem to be only improved in patients with DCM, in the levosimendan sub-group, and in patients with SR/PM. CONCLUSION: Patients with acute decompensated HF benefit from positive inotropic therapy during short-term follow-ups. In particular, patients with DCM, those after levosimendan therapy and those with SR/PM, seem to benefit most from inotropic therapy.
No takes yet. Share an insight, caveat, or question.
Cheko et al. (2023) conducted a cohort in Acute decompensated heart failure (n=50). Dobutamine or Levosimendan vs. Baseline (pre-treatment) was evaluated on NT-proBNP levels (pg/mL) (p=<0.001). Positive inotropic therapy with dobutamine or levosimendan significantly reduced NT-proBNP levels from 15765 to 6984 pg/mL and improved GFR in patients with acute decompensated heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: